Clinical-stage Australian biotech company HaemaLogiX has entered into a co-development agreement with the Peter MacCallum Cancer Centre to conduct the first-in-human Phase 1 trial of its CAR-T immunotherapy, KMA.CAR-T, for kappa-type multiple myeloma. …
HaemaLogiX and Peter MacCallum Cancer Centre announce CAR-T clinical trial agreement
July 26, 2023 Australian Biotech
Latest Video
New Stories
-
Eight women named finalists for 2026 Marie Krogh Young Women in Science Prize
September 17, 2026 - - Latest News -
Your success makes you a target and take it as a compliment
September 16, 2026 - -
From constitutional promise to creaking system - the PBS at 80
September 16, 2026 - - Latest News -
Young Australians badly misjudge when fertility starts to decline, new survey finds
September 16, 2026 - - Latest News -
New research points to a 'Doctor gap' holding back clinical trial participation in Australia
September 16, 2026 - - Latest News -
New Zealand ranks last among wealthy nations on modern medicines access, new report finds
September 16, 2026 - - Latest News -
A shorter name and bolder blue for Novo in global rebrand
September 15, 2026 - - Latest News